Scott. M. Rocklage has been a managing partner of 5 AM Ventures since 2004, where he had joined the previous year as a venture partner. With over two decades’ experience in healthcare management and his imperative leadership skills, Dr. Scott has led to FDA approval of three new U.S. drug applications (Omniscan™, Teslascan®, and Cubicin®).
Dr. Scott. M. Rocklage currently based in the Waltham, Ma office, acquired his B.S in Chemistry from University of California, Berkeley. He got his Ph.D. from the University of Massachusetts Institute of Technology (MIT) where he did research in the lab of Richard R. Schrock, an award winner in the field of chemistry, 2005.
Dr. Rocklage had held various positions in the healthcare industry. He was once the head and CEO of Cubist Pharmaceuticals and Nycomed Salutar. In addition, he led Nycomed Inventional as president, CEO and Chairman. Dr. Scott explored various R$D positions at Salutar and Catalytica. He also worked at Ilypsa(obtained by Amgen) and Miikana (obtained by EntreMed) as the prime chairman.
Dr. Scott has played a significant role in the invention of over 30 U.S. patents. He has significant peer-reviewed publications to more than a hundred and resume him.
Dr. Rocklage is currently the board chairman of Achaogen, Relypsa and Semprus. He also chairs other organization boards like Waverx, Pulmatrix and Variation. He is also the chairman of the Whitehead Institute Board of Associates and Scott’s lacrosse camp.
In a nutshell
Dr. Rocklage has made tremendous evolutions in the healthcare management systems around the U.S. He has indeed brought to the table what most organizations aspire to have and learn more about Scott.